Carvedilol Versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass Surgery
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Postoperative new-onset atrial fibrillation (AF) is the most common complication stemming
from coronary artery bypass graft surgery, and is associated with increased early and late
mortality risk. Standard guidelines recommend β blockers for the prevention of AF; however,
no prospective study has compared the relative efficacy of β-blocking agents. We hypothesize
that carvedilol, a non-selective adrenergic blocker with both anti-inflammatory and
antioxidant properties, is more effective than metoprolol, a conventional β1-selective
antagonist, in suppressing new-onset AF following off-pump coronary bypass surgery. We have
designed the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled
Trial (COMPACT) to test our hypothesis in a multi-center, open-label, and randomized
controlled trial.